Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.
Revenue (Most Recent Fiscal Year) | $78.59M |
Net Income (Most Recent Fiscal Year) | $-146.96M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 27.31 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.93 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -186.99% |
Net Margin (Trailing 12 Months) | -187.00% |
Return on Equity (Trailing 12 Months) | -34.83% |
Return on Assets (Trailing 12 Months) | -25.30% |
Current Ratio (Most Recent Fiscal Quarter) | 4.73 |
Quick Ratio (Most Recent Fiscal Quarter) | 4.73 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $7.12 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.25 |
Earnings per Share (Most Recent Fiscal Year) | $-2.52 |
Diluted Earnings per Share (Trailing 12 Months) | $-2.52 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 61.11M |
Free Float | 50.92M |
Market Capitalization | $2.15B |
Average Volume (Last 20 Days) | 0.47M |
Beta (Past 60 Months) | 2.27 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 16.67% |
Percentage Held By Institutions (Latest 13F Reports) | -- |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |